(Q44643260)

5 December 2017

title

Dermatologic side effects associated with gefitinib therapy: clinical experience and management (English)

1 reference

5 December 2017

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management (English)

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

28 March 2024

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

28 March 2024

1

Roy S Herbst

1 reference

5 December 2017

Michele Purdom

3

1 reference

5 December 2017

Deborah Ward

4

1 reference

5 December 2017

Patricia M. LoRusso

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14599302

28 March 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S1525730411703060?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

https://api.elsevier.com/content/article/PII:S1525730411703060?httpAccept=text/plain

28 March 2024

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

28 March 2024

1 reference

5 December 2017

volume

4

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

366-369

1 reference

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer

5 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

ZD1839 (Iressa): for more than just non-small cell lung cancer

28 March 2024

2

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

28 March 2024

3

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Epidermal growth factor-related peptides and their receptors in human malignancies

28 March 2024

4

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

ZD1839 (Iressa) in non-small cell lung cancer

28 March 2024

5

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

The epidermal growth factor receptor and its inhibition in cancer therapy

28 March 2024

6

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Why the epidermal growth factor receptor? The rationale for cancer therapy

28 March 2024

7

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

28 March 2024

8

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

28 March 2024

9

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

28 March 2024

10

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

28 March 2024

11

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Tyrosine kinase inhibitors-ZD1839 (Iressa).

28 March 2024

12

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

28 March 2024

14

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy

28 March 2024

15

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

28 March 2024

16

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development

28 March 2024

17

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.016

28 March 2024

Identifiers

1 reference

5 December 2017

1 reference